CombiGene Past Earnings Performance
Past criteria checks 0/6
CombiGene has been growing earnings at an average annual rate of 7.6%, while the Biotechs industry saw earnings growing at 15.7% annually. Revenues have been growing at an average rate of 23.4% per year.
Key information
7.6%
Earnings growth rate
47.0%
EPS growth rate
Biotechs Industry Growth | 0.7% |
Revenue growth rate | 23.4% |
Return on equity | -30.6% |
Net Margin | -508.9% |
Next Earnings Update | 17 May 2024 |
Revenue & Expenses BreakdownBeta
How CombiGene makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 7 | -36 | 15 | 0 |
30 Sep 23 | -8 | -41 | 15 | 0 |
30 Jun 23 | 4 | -29 | 15 | 0 |
31 Mar 23 | 17 | -18 | 14 | 0 |
31 Dec 22 | 29 | -6 | 13 | 0 |
30 Sep 22 | 127 | 63 | 14 | 0 |
30 Jun 22 | 114 | 49 | 13 | 0 |
31 Mar 22 | 100 | 29 | 12 | 0 |
31 Dec 21 | 91 | 21 | 12 | 0 |
30 Sep 21 | 8 | -47 | -9 | 0 |
30 Jun 21 | 11 | -44 | -3 | 0 |
31 Mar 21 | 12 | -33 | 0 | 0 |
31 Dec 20 | 11 | -29 | 7 | 0 |
30 Sep 20 | 12 | -27 | 35 | 0 |
30 Jun 20 | 16 | -24 | 36 | 0 |
31 Mar 20 | 17 | -23 | 37 | 0 |
31 Dec 19 | 15 | -18 | 31 | 0 |
30 Sep 19 | 13 | -12 | 20 | 0 |
30 Jun 19 | 8 | -14 | 8 | 0 |
31 Mar 19 | 5 | -14 | 4 | 0 |
31 Dec 18 | 4 | -13 | 2 | 0 |
30 Sep 18 | 2 | -13 | 2 | 0 |
30 Jun 18 | 1 | -10 | 5 | 0 |
31 Mar 18 | 1 | -11 | 4 | 0 |
31 Dec 17 | 3 | -9 | 2 | 0 |
30 Sep 17 | 3 | -8 | 2 | 0 |
30 Jun 17 | 3 | -8 | 2 | 0 |
31 Mar 17 | 3 | -7 | 2 | 0 |
31 Dec 16 | 0 | -9 | 1 | 0 |
30 Sep 16 | 0 | -8 | 4 | 0 |
30 Jun 16 | 0 | -7 | 4 | 0 |
31 Mar 16 | 0 | -7 | 6 | 0 |
31 Dec 15 | 0 | -6 | 6 | 0 |
30 Sep 15 | 0 | -5 | 5 | 0 |
30 Jun 15 | 0 | -4 | 4 | 0 |
31 Mar 15 | 0 | -2 | 2 | 0 |
31 Dec 14 | 0 | -1 | 1 | 0 |
Quality Earnings: COMBI is currently unprofitable.
Growing Profit Margin: COMBI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: COMBI is unprofitable, but has reduced losses over the past 5 years at a rate of 7.6% per year.
Accelerating Growth: Unable to compare COMBI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: COMBI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Return on Equity
High ROE: COMBI has a negative Return on Equity (-30.63%), as it is currently unprofitable.